CD19 and systemic lupus erythematosus: We have also demonstrated that anti-CD19 CAR T-cells manufactured from patients with treatment-refractory SLE are fully functional and exhibit CAR-mediated and CD19-dependent cytokine release when co-cultured with autologous primary B-cells [12,13].